Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Author Correction: Development of new method to enrich human iPSC-derived renal progenitors using cell surface markers.

Hoshina A, Kawamoto T, Sueta SI, Mae SI, Araoka T, Tanaka H, Sato Y, Yamagishi Y, Osafune K.

Sci Rep. 2019 Jul 18;9(1):10701. doi: 10.1038/s41598-019-46254-0.

2.

Novel hybrid three-dimensional artificial liver using human induced pluripotent stem cells and a rat decellularized liver scaffold.

Minami T, Ishii T, Yasuchika K, Fukumitsu K, Ogiso S, Miyauchi Y, Kojima H, Kawai T, Yamaoka R, Oshima Y, Kawamoto H, Kotaka M, Yasuda K, Osafune K, Uemoto S.

Regen Ther. 2019 Mar 30;10:127-133. doi: 10.1016/j.reth.2019.03.002. eCollection 2019 Jun.

3.

Efficient Generation of Pancreas/Duodenum Homeobox Protein 1+ Posterior Foregut/Pancreatic Progenitors from hPSCs in Adhesion Cultures.

Toyoda T, Kimura A, Tanaka H, Osafune K.

J Vis Exp. 2019 Mar 27;(145). doi: 10.3791/57641.

PMID:
30985740
4.

[Dissecting early development of the kidney by single cell transcriptomics].

Sakamoto S, Mae SI, Osafune K, Okada C, Kabai R, Watanabe A.

Nihon Yakurigaku Zasshi. 2019;153(2):61-66. doi: 10.1254/fpj.153.61. Japanese.

PMID:
30745515
5.

Protocol to Generate Ureteric Bud Structures from Human iPS Cells.

Mae SI, Ryosaka M, Osafune K.

Methods Mol Biol. 2019;1926:117-123. doi: 10.1007/978-1-4939-9021-4_10.

PMID:
30742267
6.

Differentiation and isolation of iPSC-derived remodeling ductal plate-like cells by use of an AQP1-GFP reporter human iPSC line.

Matsui S, Ochiai M, Yasuda K, Mae SI, Kotaka M, Toyoda T, Yamamoto T, Osafune K.

Stem Cell Res. 2019 Mar;35:101400. doi: 10.1016/j.scr.2019.101400. Epub 2019 Jan 31.

7.

Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development.

Karagiannis P, Takahashi K, Saito M, Yoshida Y, Okita K, Watanabe A, Inoue H, Yamashita JK, Todani M, Nakagawa M, Osawa M, Yashiro Y, Yamanaka S, Osafune K.

Physiol Rev. 2019 Jan 1;99(1):79-114. doi: 10.1152/physrev.00039.2017. Review.

PMID:
30328784
8.

[Current status and future perspective of regenerative medicine for the pancreas].

Mima A, Toyoda T, Osafune K.

Nihon Shokakibyo Gakkai Zasshi. 2018;115(8):681-690. doi: 10.11405/nisshoshi.115.681. Japanese. No abstract available.

PMID:
30101868
9.

Development of new method to enrich human iPSC-derived renal progenitors using cell surface markers.

Hoshina A, Kawamoto T, Sueta SI, Mae SI, Araoka T, Tanaka H, Sato Y, Yamagishi Y, Osafune K.

Sci Rep. 2018 Apr 23;8(1):6375. doi: 10.1038/s41598-018-24714-3. Erratum in: Sci Rep. 2019 Jul 18;9(1):10701.

10.

Adrenergic receptor agonists induce the differentiation of pluripotent stem cell-derived hepatoblasts into hepatocyte-like cells.

Kotaka M, Toyoda T, Yasuda K, Kitano Y, Okada C, Ohta A, Watanabe A, Uesugi M, Osafune K.

Sci Rep. 2017 Dec 1;7(1):16734. doi: 10.1038/s41598-017-16858-5.

11.

Generation of branching ureteric bud tissues from human pluripotent stem cells.

Mae SI, Ryosaka M, Toyoda T, Matsuse K, Oshima Y, Tsujimoto H, Okumura S, Shibasaki A, Osafune K.

Biochem Biophys Res Commun. 2018 Jan 1;495(1):954-961. doi: 10.1016/j.bbrc.2017.11.105. Epub 2017 Nov 20.

PMID:
29158085
12.

Significance of dopamine D1 receptor signalling for steroidogenic differentiation of human induced pluripotent stem cells.

Matsuo K, Sone M, Honda-Kohmo K, Toyohara T, Sonoyama T, Taura D, Kojima K, Fukuda Y, Ohno Y, Inoue M, Ohta A, Osafune K, Nakao K, Inagaki N.

Sci Rep. 2017 Nov 9;7(1):15120. doi: 10.1038/s41598-017-15485-4.

13.

Beta-cell replacement strategies for diabetes.

Kieffer TJ, Woltjen K, Osafune K, Yabe D, Inagaki N.

J Diabetes Investig. 2017 Oct 6. doi: 10.1111/jdi.12758. [Epub ahead of print] Review.

14.

Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice.

Hitomi H, Kasahara T, Katagiri N, Hoshina A, Mae SI, Kotaka M, Toyohara T, Rahman A, Nakano D, Niwa A, Saito MK, Nakahata T, Nishiyama A, Osafune K.

Sci Transl Med. 2017 Sep 27;9(409). pii: eaaj2300. doi: 10.1126/scitranslmed.aaj2300.

PMID:
28954928
15.

Small molecule AT7867 proliferates PDX1-expressing pancreatic progenitor cells derived from human pluripotent stem cells.

Kimura A, Toyoda T, Nishi Y, Nasu M, Ohta A, Osafune K.

Stem Cell Res. 2017 Oct;24:61-68. doi: 10.1016/j.scr.2017.08.010. Epub 2017 Aug 17.

16.

Insulin-producing cells derived from 'induced pluripotent stem cells' of patients with fulminant type 1 diabetes: Vulnerability to cytokine insults and increased expression of apoptosis-related genes.

Hosokawa Y, Toyoda T, Fukui K, Baden MY, Funato M, Kondo Y, Sudo T, Iwahashi H, Kishida M, Okada C, Watanabe A, Asaka I, Osafune K, Imagawa A, Shimomura I.

J Diabetes Investig. 2017 Aug 10. doi: 10.1111/jdi.12727. [Epub ahead of print]

17.

Rho-Associated Kinases and Non-muscle Myosin IIs Inhibit the Differentiation of Human iPSCs to Pancreatic Endoderm.

Toyoda T, Kimura A, Tanaka H, Ameku T, Mima A, Hirose Y, Nakamura M, Watanabe A, Osafune K.

Stem Cell Reports. 2017 Aug 8;9(2):419-428. doi: 10.1016/j.stemcr.2017.07.005.

18.

iPSC technology-based regenerative therapy for diabetes.

Kondo Y, Toyoda T, Inagaki N, Osafune K.

J Diabetes Investig. 2018 Mar;9(2):234-243. doi: 10.1111/jdi.12702. Epub 2017 Jul 29. Review.

19.

Identification of a small molecule that facilitates the differentiation of human iPSCs/ESCs and mouse embryonic pancreatic explants into pancreatic endocrine cells.

Kondo Y, Toyoda T, Ito R, Funato M, Hosokawa Y, Matsui S, Sudo T, Nakamura M, Okada C, Zhuang X, Watanabe A, Ohta A, Inagaki N, Osafune K.

Diabetologia. 2017 Aug;60(8):1454-1466. doi: 10.1007/s00125-017-4302-7. Epub 2017 May 22.

PMID:
28534195
20.

Corrigendum to "Modelling urea-cycle disorder citrullinemia type 1 with disease-specific iPSCs" [Biochem. Biophys. Res. Commun. 486(3) (2017) 613-619].

Yoshitoshi-Uebayashi EY, Toyoda T, Yasuda K, Kotaka M, Nomoto K, Okita K, Yasuchika K, Okamoto S, Takubo N, Nishikubo T, Soga T, Uemoto S, Osafune K.

Biochem Biophys Res Commun. 2017 Jul 1;488(3):570-571. doi: 10.1016/j.bbrc.2017.05.055. Epub 2017 May 18. No abstract available.

PMID:
28528898
21.

Modelling urea-cycle disorder citrullinemia type 1 with disease-specific iPSCs.

Yoshitoshi-Uebayashi EY, Toyoda T, Yasuda K, Kotaka M, Nomoto K, Okita K, Yasuchika K, Okamoto S, Takubo N, Nishikubo T, Soga T, Uemoto S, Osafune K.

Biochem Biophys Res Commun. 2017 May 6;486(3):613-619. doi: 10.1016/j.bbrc.2017.03.037. Epub 2017 Mar 14. Erratum in: Biochem Biophys Res Commun. 2017 Jul 1;488(3):570-571.

PMID:
28302489
22.

Transcriptional Analysis of Intravenous Immunoglobulin Resistance in Kawasaki Disease Using an Induced Pluripotent Stem Cell Disease Model.

Ikeda K, Mizoro Y, Ameku T, Nomiya Y, Mae SI, Matsui S, Kuchitsu Y, Suzuki C, Hamaoka-Okamoto A, Yahata T, Sone M, Okita K, Watanabe A, Osafune K, Hamaoka K.

Circ J. 2016 Dec 22;81(1):110-118. doi: 10.1253/circj.CJ-16-0541. Epub 2016 Nov 19.

23.

Identification of MMP1 as a novel risk factor for intracranial aneurysms in ADPKD using iPSC models.

Ameku T, Taura D, Sone M, Numata T, Nakamura M, Shiota F, Toyoda T, Matsui S, Araoka T, Yasuno T, Mae S, Kobayashi H, Kondo N, Kitaoka F, Amano N, Arai S, Ichisaka T, Matsuura N, Inoue S, Yamamoto T, Takahashi K, Asaka I, Yamada Y, Ubara Y, Muso E, Fukatsu A, Watanabe A, Sato Y, Nakahata T, Mori Y, Koizumi A, Nakao K, Yamanaka S, Osafune K.

Sci Rep. 2016 Jul 15;6:30013. doi: 10.1038/srep30013.

24.

[Current status and perspective of regenerative medicine for diabetic nephropathy].

Matsui S, Osafune K.

Nihon Rinsho. 2016 Apr;74 Suppl 2:207-11. Japanese. No abstract available.

PMID:
27266089
25.

Redefining definitive endoderm subtypes by robust induction of human induced pluripotent stem cells.

Matsuno K, Mae SI, Okada C, Nakamura M, Watanabe A, Toyoda T, Uchida E, Osafune K.

Differentiation. 2016 Dec;92(5):281-290. doi: 10.1016/j.diff.2016.04.002. Epub 2016 Apr 14.

PMID:
27087651
26.

[Towards the Clinical Application of iPS Cell Technology for the Treatment of Kidney Diseases].

Osafune K.

Rinsho Byori. 2015 Feb;63(2):265-73. Review. Japanese.

PMID:
26529981
27.

Cell Therapy Using Human Induced Pluripotent Stem Cell-Derived Renal Progenitors Ameliorates Acute Kidney Injury in Mice.

Toyohara T, Mae S, Sueta S, Inoue T, Yamagishi Y, Kawamoto T, Kasahara T, Hoshina A, Toyoda T, Tanaka H, Araoka T, Sato-Otsubo A, Takahashi K, Sato Y, Yamaji N, Ogawa S, Yamanaka S, Osafune K.

Stem Cells Transl Med. 2015 Sep;4(9):980-92. doi: 10.5966/sctm.2014-0219. Epub 2015 Jul 21.

28.

iPS cells and kidney diseases.

Inoue T, Osafune K.

Nihon Rinsho. 2015 Jun;73 Suppl 5:170-4. Japanese. No abstract available.

PMID:
30457771
29.

Efficient Detection and Purification of Cell Populations Using Synthetic MicroRNA Switches.

Miki K, Endo K, Takahashi S, Funakoshi S, Takei I, Katayama S, Toyoda T, Kotaka M, Takaki T, Umeda M, Okubo C, Nishikawa M, Oishi A, Narita M, Miyashita I, Asano K, Hayashi K, Osafune K, Yamanaka S, Saito H, Yoshida Y.

Cell Stem Cell. 2015 Jun 4;16(6):699-711. doi: 10.1016/j.stem.2015.04.005. Epub 2015 May 21.

30.

Vascularized and Complex Organ Buds from Diverse Tissues via Mesenchymal Cell-Driven Condensation.

Takebe T, Enomura M, Yoshizawa E, Kimura M, Koike H, Ueno Y, Matsuzaki T, Yamazaki T, Toyohara T, Osafune K, Nakauchi H, Yoshikawa HY, Taniguchi H.

Cell Stem Cell. 2015 May 7;16(5):556-65. doi: 10.1016/j.stem.2015.03.004. Epub 2015 Apr 16.

31.

Kidney regeneration from human induced pluripotent stem cells.

Mae S, Osafune K.

Curr Opin Organ Transplant. 2015 Apr;20(2):171-7. doi: 10.1097/MOT.0000000000000170. Review.

PMID:
25856179
32.

Cell aggregation optimizes the differentiation of human ESCs and iPSCs into pancreatic bud-like progenitor cells.

Toyoda T, Mae S, Tanaka H, Kondo Y, Funato M, Hosokawa Y, Sudo T, Kawaguchi Y, Osafune K.

Stem Cell Res. 2015 Mar;14(2):185-97. doi: 10.1016/j.scr.2015.01.007. Epub 2015 Jan 28.

33.

Generation of alveolar epithelial spheroids via isolated progenitor cells from human pluripotent stem cells.

Gotoh S, Ito I, Nagasaki T, Yamamoto Y, Konishi S, Korogi Y, Matsumoto H, Muro S, Hirai T, Funato M, Mae S, Toyoda T, Sato-Otsubo A, Ogawa S, Osafune K, Mishima M.

Stem Cell Reports. 2014 Sep 9;3(3):394-403. doi: 10.1016/j.stemcr.2014.07.005. Epub 2014 Aug 21.

34.

Cell therapy for kidney injury: different options and mechanisms--kidney progenitor cells.

Osafune K.

Nephron Exp Nephrol. 2014;126(2):64. doi: 10.1159/000360668. Epub 2014 May 19. Review.

35.

Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency.

Yasuno T, Osafune K, Sakurai H, Asaka I, Tanaka A, Yamaguchi S, Yamada K, Hitomi H, Arai S, Kurose Y, Higaki Y, Sudo M, Ando S, Nakashima H, Saito T, Kaneoka H.

Biochem Biophys Res Commun. 2014 May 30;448(2):175-81. doi: 10.1016/j.bbrc.2014.04.084. Epub 2014 Apr 26.

PMID:
24780397
36.

Induction of pluripotency in human somatic cells via a transient state resembling primitive streak-like mesendoderm.

Takahashi K, Tanabe K, Ohnuki M, Narita M, Sasaki A, Yamamoto M, Nakamura M, Sutou K, Osafune K, Yamanaka S.

Nat Commun. 2014 Apr 24;5:3678. doi: 10.1038/ncomms4678.

PMID:
24759836
37.

Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation.

Ohnishi K, Semi K, Yamamoto T, Shimizu M, Tanaka A, Mitsunaga K, Okita K, Osafune K, Arioka Y, Maeda T, Soejima H, Moriwaki H, Yamanaka S, Woltjen K, Yamada Y.

Cell. 2014 Feb 13;156(4):663-77. doi: 10.1016/j.cell.2014.01.005.

38.

Efficient and rapid induction of human iPSCs/ESCs into nephrogenic intermediate mesoderm using small molecule-based differentiation methods.

Araoka T, Mae S, Kurose Y, Uesugi M, Ohta A, Yamanaka S, Osafune K.

PLoS One. 2014 Jan 15;9(1):e84881. doi: 10.1371/journal.pone.0084881. eCollection 2014.

39.

[New therapeutic insights for chronic kidney disease provided by podocytology].

Inoue R, Asanuma K, Seki T, Nagase M, Osafune K.

Nihon Yakurigaku Zasshi. 2014 Jan;143(1):27-33. Review. Japanese. No abstract available.

PMID:
24420134
40.

A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells.

Nakagawa M, Taniguchi Y, Senda S, Takizawa N, Ichisaka T, Asano K, Morizane A, Doi D, Takahashi J, Nishizawa M, Yoshida Y, Toyoda T, Osafune K, Sekiguchi K, Yamanaka S.

Sci Rep. 2014 Jan 8;4:3594. doi: 10.1038/srep03594.

41.

Will it be possible to generate kidney tissue from induced pluripotent stem cells for regenerative therapy?

Osafune K.

Regen Med. 2014 Jan;9(1):9-12. doi: 10.2217/rme.13.84. No abstract available.

PMID:
24351001
42.

The moyamoya disease susceptibility variant RNF213 R4810K (rs112735431) induces genomic instability by mitotic abnormality.

Hitomi T, Habu T, Kobayashi H, Okuda H, Harada KH, Osafune K, Taura D, Sone M, Asaka I, Ameku T, Watanabe A, Kasahara T, Sudo T, Shiota F, Hashikata H, Takagi Y, Morito D, Miyamoto S, Nakao K, Koizumi A.

Biochem Biophys Res Commun. 2013 Oct 4;439(4):419-26. doi: 10.1016/j.bbrc.2013.08.067. Epub 2013 Aug 27.

PMID:
23994138
43.

Downregulation of Securin by the variant RNF213 R4810K (rs112735431, G>A) reduces angiogenic activity of induced pluripotent stem cell-derived vascular endothelial cells from moyamoya patients.

Hitomi T, Habu T, Kobayashi H, Okuda H, Harada KH, Osafune K, Taura D, Sone M, Asaka I, Ameku T, Watanabe A, Kasahara T, Sudo T, Shiota F, Hashikata H, Takagi Y, Morito D, Miyamoto S, Nakao K, Koizumi A.

Biochem Biophys Res Commun. 2013 Aug 16;438(1):13-9. doi: 10.1016/j.bbrc.2013.07.004. Epub 2013 Jul 12.

PMID:
23850618
44.

Genetically matched human iPS cells reveal that propensity for cartilage and bone differentiation differs with clones, not cell type of origin.

Nasu A, Ikeya M, Yamamoto T, Watanabe A, Jin Y, Matsumoto Y, Hayakawa K, Amano N, Sato S, Osafune K, Aoyama T, Nakamura T, Kato T, Toguchida J.

PLoS One. 2013;8(1):e53771. doi: 10.1371/journal.pone.0053771. Epub 2013 Jan 31.

45.

Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells.

Mae SI, Shono A, Shiota F, Yasuno T, Kajiwara M, Gotoda-Nishimura N, Arai S, Sato-Otubo A, Toyoda T, Takahashi K, Nakayama N, Cowan CA, Aoi T, Ogawa S, McMahon AP, Yamanaka S, Osafune K.

Nat Commun. 2013;4:1367. doi: 10.1038/ncomms2378.

46.

[iPS cell technology-based strategies for the treatment of diabetic nephropathy].

Osafune K.

Nihon Rinsho. 2012 Jul;70 Suppl 5:419-23. Japanese. No abstract available.

PMID:
23156431
47.

iPS cell technology-based research for the treatment of diabetic nephropathy.

Osafune K.

Semin Nephrol. 2012 Sep;32(5):479-85. doi: 10.1016/j.semnephrol.2012.07.011. Review.

PMID:
23062989
48.

In vitro regeneration of kidney from pluripotent stem cells.

Osafune K.

Exp Cell Res. 2010 Oct 1;316(16):2571-7. doi: 10.1016/j.yexcr.2010.04.034. Epub 2010 May 6. Review.

PMID:
20451514
49.

A small molecule that directs differentiation of human ESCs into the pancreatic lineage.

Chen S, Borowiak M, Fox JL, Maehr R, Osafune K, Davidow L, Lam K, Peng LF, Schreiber SL, Rubin LL, Melton D.

Nat Chem Biol. 2009 Apr;5(4):258-65. doi: 10.1038/nchembio.154. Epub 2009 Mar 15.

PMID:
19287398
50.

Induced pluripotent stem (iPS) cells: an up-to-the-minute review.

Lau F, Ahfeldt T, Osafune K, Akustsu H, Cowan CA.

F1000 Biol Rep. 2009 Nov 16;1:84. doi: 10.3410/B1-84.

Supplemental Content

Loading ...
Support Center